Is ritexitinib expensive to treat alopecia areata? How patients can reduce treatment costs

Ritlecitinib as a newJanus kinase (JAK) and TEC kinase inhibitor, is used to treat severe Alopecia Areata (Alopecia Areata), and its efficacy is supported by clinical studies. However, one of the major problems faced by patients is the high cost of its treatment. At present, the original drug of ritexitinib has been approved in China, but it has not yet been included in the scope of medical insurance reimbursement, so patients need to bear all the drug costs themselves. In the domestic market, the common specification of this drug is 50mg*30 tablets, and each box may be sold for about more than 3,000 yuan. The treatment of alopecia areata usually requires continuous use for several months or even longer, which undoubtedly increases the financial burden of patients.

Compared with the domestic market, the price of ritexitinib in overseas markets is higher. For example, the European version of the original drug usually sells for more than RMB 10,000 per box, and the specific price will be affected by exchange rate fluctuations. In addition, some countries have different drug pricing policies, resulting in large differences in the selling price of the drug in different markets. For patients who require long-term use, the high price can be a major barrier to treatment.

In order to reduce the cost of treatment, some patients choose to purchase overseas generic drugs. For example, the Lao version of the generic version of ritexitinib is already on the market. Its main ingredients are roughly the same as the original drug, but the price is relatively low, about more than 700 yuan per box. However, there may be certain differences in the production standards, effectiveness, and safety of generic drugs, so patients need to be cautious when choosing and ensure that they are purchased through formal channels to ensure the quality and efficacy of the drugs.

In addition, there are several ways that patients can consider reducing the cost of treatment. For example, pay attention to domestic and foreign drug preferential policies. Some countries or regions may provide patient assistance programs or drug discounts. At the same time, some cross-border e-commerce platforms or international drug purchasing agencies may also provide relatively preferential prices. For domestic patients, if ritexitinib can be included in the medical insurance catalog in the future, the cost of treatment will drop significantly, so it is recommended to pay close attention to adjustments to the medical insurance policy.

Reference materials:https://www.litfulo.com/